{
    "clinical_study": {
        "@rank": "105977", 
        "acronym": "ECLIPSE", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "cyclophosphamide (200 mg/m^2) D0 of Weeks 1, 4\nGVAX Pancreas Vaccine (5 \u00d7 10e8 cells) D 1 of Weeks 1, 4\nCRS-207 (1 \u00d7 10e9 CFU) Weeks 7, 10, 13, 16"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Experimental", 
                "description": "CRS-207 Weeks 1, 4, 7, 10, 13, 16"
            }, 
            {
                "arm_group_label": "C", 
                "arm_group_type": "Active Comparator", 
                "description": "chemotherapy: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib in accordance with defined treatment schedule"
            }
        ], 
        "brief_summary": {
            "textblock": "Test the safety, immune response and efficacy of GVAX pancreas vaccine (with\n      cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with\n      previously treated metastatic pancreatic adenocarcinoma"
        }, 
        "brief_title": "Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting", 
        "condition": "2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have histologically proven malignant adenocarcinoma of the pancreas; measurable\n             disease is not required, mixed histology is not allowed; subjects must have\n             metastatic disease\n\n          -  2nd line, 3rd line or greater\n\n          -  At least 18 years of age\n\n          -  ECOG of 0 or 1\n\n          -  Anticipated life expectancy >12 weeks\n\n          -  For women and men of childbearing potential, a medically acceptable method of highly\n             effective contraception (oral hormonal contraceptive, condom plus spermicide, or\n             hormone implants) must be used throughout the study period and for 28 days after\n             their final vaccine administration. (A barrier method of contraception must be\n             employed by all subjects [male and female], regardless of other methods.)\n\n          -  Have adequate organ function as defined by specified laboratory values\n\n        Exclusion Criteria:\n\n          -  Allergy to both penicillin & sulfa or suspected hypersensitivity to GM-CSF, dimethyl\n             sulfoxide, fetal bovine serum, trypsin, yeast, glycerol or other component of the\n             therapy options\n\n          -  Known history or evidence of brain metastases, immunodeficiency disease or\n             immunocompromised state or or history of autoimmune disease requiring systemic\n             steroids or other immunosuppressive treatment\n\n          -  Have any evidence of hepatic cirrhosis or clinical or radiographic ascites\n\n          -  A prosthetic joint or other artificial implant or device that cannot be easily\n             removed (there are some exceptions)\n\n          -  Rapidly progressing disease\n\n          -  Clinically significant and/or malignant pleural effusion\n\n          -  Received prior GVAX pancreas vaccine or CRS-207\n\n          -  Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring\n             within 28 days prior to receiving study drug, or planned surgery requiring general\n             anesthesia\n\n          -  Infection with HIV or hepatitis B or C at screening\n\n          -  Valvular heart disease that requires antibiotic prophylaxis for prevention of\n             endocarditis\n\n          -  Be pregnant or breastfeeding\n\n          -  Unable to avoid close contact with another individual known to be at high risk of\n             listeriosis (e.g., newborn infant, pregnant woman, HIV-positive individual) during\n             the course of CRS-207 treatment until completion of antibiotic regimen\n\n          -  Conditions, including alcohol or drug dependence, intercurrent illness, or lack of\n             sufficient peripheral venous access, that would affect the patient's ability to\n             comply with study visits and procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004262", 
            "org_study_id": "ADU-CL-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "intervention_name": "GVAX Pancreas Vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "A", 
                    "B"
                ], 
                "intervention_name": "CRS-207", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "C", 
                "intervention_name": "gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "A", 
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Cytoxan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Gemcitabine", 
                "Irinotecan", 
                "Capecitabine", 
                "Pancreatin", 
                "Pancrelipase", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "cancer", 
            "cancer vaccine", 
            "Listeria monocytogenes", 
            "Listeria-based vaccine", 
            "GVAX", 
            "cyclophosphamide", 
            "Cytoxan", 
            "immunotherapy", 
            "mesothelin"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "link": [
            {
                "description": "For additional information please see Aduro's website", 
                "url": "http://www.adurobiotech.com"
            }, 
            {
                "description": "The Pancreatic Cancer Action Network's Patient & Liaison Services (PALS) program provides patients and families with information and resources at no cost. Visit www.pancan.org, call 877-272-6226 or email pals@pancan.org for information.", 
                "url": "http://www.pancan.org"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "joschaffer@shc.org", 
                    "last_name": "Joyce Schaffer, MSN RN AOCNS", 
                    "phone": "480-323-1339", 
                    "phone_ext": "2"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "Scottsdale Healthcare Research Institute"
                }, 
                "investigator": {
                    "last_name": "Erkut Borazanci, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "JAMIE.BENDRICK-PEART@UCDENVER.EDU", 
                    "last_name": "Jamie Bendrick-Peart", 
                    "phone": "720-848-0600"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Denver"
                }, 
                "investigator": {
                    "last_name": "Colin Weekes, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "besimpson@ucsd.edu", 
                    "last_name": "Brian Simpson", 
                    "phone": "858-822-7951"
                }, 
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92037"
                    }, 
                    "name": "University California San Diego Moores Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Tony Reid, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "NickersonM@cc.ucsf.edu", 
                    "last_name": "McKinley Nickerson", 
                    "phone": "415-514-6314"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "University of California Mt Zion Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Andrew Ko, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "J.Forrester@med.miami.edu", 
                    "last_name": "Jasmine Forrester", 
                    "phone": "305-243-0865"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami/Sylvester Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Peter Hosein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Kallen@bsd.uchicago.edu", 
                    "last_name": "Kenisha Allen", 
                    "phone": "773-834-0475"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago Medical Center"
                }, 
                "investigator": {
                    "last_name": "Hedy Kindler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Hkember1@jhmi.edu", 
                    "last_name": "Holly Kemberling, RN", 
                    "phone": "443-287-5013"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "investigator": {
                    "last_name": "Dung Le, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "klears@dom.wustl.edu", 
                    "last_name": "Kimberly Lears", 
                    "phone": "314-747-8085"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University"
                }, 
                "investigator": {
                    "last_name": "Andrea Wang-Gillam, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "amo2135@columbia.edu", 
                    "last_name": "Anna Oprescu", 
                    "phone": "212-304-5588"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Robert Fine, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ireka.burrus@duke.edu", 
                    "last_name": "Ireka Burrus", 
                    "phone": "919-668-1861"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center Morris Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Michael Morse, MD, MHS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yue-yun.to@providence.org", 
                    "last_name": "Yue-Yun To", 
                    "phone": "503-215-2855"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97213"
                    }, 
                    "name": "Providence Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Todd Crocenzi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gtribble@upmc.edu", 
                    "last_name": "Gail Tribble", 
                    "phone": "412-647-8205"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }, 
                    "name": "University of Pittsburgh Medical Center Cancer Pavillion"
                }, 
                "investigator": {
                    "last_name": "Herbert Zeh III, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "VICC Cancer Information Program", 
                    "phone": "800-811-8480"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37215"
                    }, 
                    "name": "Vanderbilt University"
                }, 
                "investigator": {
                    "last_name": "Emily Chan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "CMB2BT@hscmail.mcc.virginia.edu", 
                    "last_name": "Christopher Blackwell", 
                    "phone": "434-982-1901"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "University of Virginia Health System"
                }, 
                "investigator": {
                    "last_name": "Osama Rahma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "megan.pilling@vmmc.org", 
                    "last_name": "Megan Pilling", 
                    "phone": "206-342-6908"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "Virginia Mason Medical Center"
                }, 
                "investigator": {
                    "last_name": "Vincent J Picozzi, MD, MMM", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bernadette.southwood@uhn.ca", 
                    "last_name": "Bernadette Southwood", 
                    "phone": "416-946-4501", 
                    "phone_ext": "3422"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Princess Margaret Hospital Princess Margaret Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Malcolm Moore, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival in subjects receiving test treatments", 
            "safety_issue": "No", 
            "time_frame": "Subjects followed on study for 2 years from last subject enrolled; expected duration of follow-up = 3 years"
        }, 
        "reference": [
            {
                "PMID": "15365184", 
                "citation": "Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7. Epub 2004 Sep 13."
            }, 
            {
                "PMID": "22147941", 
                "citation": "Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012 Feb 1;18(3):858-68. doi: 10.1158/1078-0432.CCR-11-2121. Epub 2011 Dec 6."
            }, 
            {
                "PMID": "21217520", 
                "citation": "Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011 Feb;253(2):328-35. doi: 10.1097/SLA.0b013e3181fd271c."
            }, 
            {
                "PMID": "18316569", 
                "citation": "Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008 Mar 1;14(5):1455-63."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004262"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Adverse events in each treatment arm treatment regimen", 
            "safety_issue": "Yes", 
            "time_frame": "Subjects followed on study for 2 years from last subject enrolled; expected duration of follow-up = 3 years"
        }, 
        "source": "Aduro BioTech, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aduro BioTech, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}